



# OPEN Health risks evaluation of mycotoxins in plant-based supplements marketed in Malaysia

Rozaini Abdullah<sup>1</sup>✉, Nur Syazwin Kamarozaman<sup>1</sup>, Siti Soleha Ab Dullah<sup>2</sup>, Mohd Yusmaidie Aziz<sup>3</sup> & Hussein Bakheit Adam Aziza<sup>4,5</sup>

Mycotoxins are toxic secondary metabolites produced by fungi, pose significant health risks when present in plant-based supplements (PBS), necessitating thorough risk assessment to ensure consumer safety. This study evaluates the health risks associated with mycotoxins, specifically aflatoxins (AFB<sub>1</sub>, AFB<sub>2</sub>) and ochratoxin A (OTA), in PBS sold in Malaysia. Contamination levels of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA were quantified in 14 PBS samples using Liquid Chromatography-Mass Spectrometry. All samples tested positive for AFB<sub>2</sub>, while 28.57% and 42.86% tested positive for AFB<sub>1</sub> and OTA, respectively with some levels exceeding the regulatory limits set by the Malaysian Food Act 1983 and European regulations. The estimated daily intake of these mycotoxins was calculated based on the recommended daily intake of each supplement. To assess risk, Margin of Exposure (MOE) values were determined, showing that all AFB<sub>2</sub>-positive samples had MOE values below the critical threshold of 10,000, indicating an urgent need for risk management. A quantitative cancer risk assessment also estimated the percentage of hepatocellular carcinoma and kidney cancer attributable to mycotoxin exposure. The findings emphasize the significant public health risks posed by mycotoxins, particularly in samples B2 and B10, where all three mycotoxins studied were present at concerning levels. This study highlights the urgent need for stricter regulations and better monitoring of mycotoxin levels in PBS to protect consumer's health.

**Keywords** Mycotoxin, Aflatoxin, Ochratoxin, Risk assessment, Supplement, Margin of exposure

## Abbreviations

|                  |  |
|------------------|--|
| AFB <sub>1</sub> | Aflatoxin B1                                     |
| AFB <sub>2</sub> | Aflatoxin B2                                     |
| EDI              | Estimated daily intake                           |
| EFSA             | European food safety authority                   |
| HCC              | Hepatocellular carcinoma                         |
| JECFA            | Joint FAO/WHO expert committee on food additives |
| LB               | Lower bound                                      |
| MOE              | Margin of exposure                               |
| OTA              | Ochratoxin A                                     |
| PBS              | Plant-based supplements                          |
| UP               | Upper bound                                      |

Mycotoxins, toxic secondary metabolites produced by various fungi, present a significant public health issue, particularly in regions like Malaysia, where plant-based supplements (PBS) are regularly consumed. These supplements, derived from natural sources, are susceptible to contamination by mycotoxins, such as aflatoxins, which have been associated with serious health effects, including hepatotoxicity and carcinogenicity<sup>1,2</sup>. As the

<sup>1</sup>Department of Environmental & Occupational Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia. <sup>2</sup>Toxicology and Pharmacology Unit, Herbal Medicine Research Centre, Institute for Medical Research, National Institute of Health, Persiaran Setia Murni, Setia Alam, 40170 Shah Alam, Selangor Darul Ehsan, Malaysia. <sup>3</sup>Department of Toxicology, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang, Malaysia. <sup>4</sup>Faculty of Defense and Security, Rabdan Academy, 22401 Abu Dhabi, United Arab Emirates. <sup>5</sup>Department of Food Hygiene and Safety, Faculty of Public and Environmental Health, University of Khartoum, 11111 Khartoum, Sudan. ✉email: rozainiabdullah@upm.edu.my

use of herbal and natural supplements rises in Malaysia, concerns about the safety and quality of these products, particularly regarding mycotoxin contamination, have expanded<sup>3</sup>. Research has identified aflatoxins, particularly aflatoxin B<sub>1</sub> (AFB<sub>1</sub>), a potent carcinogen, in many herbal products, posing substantial health risks to consumers who rely on these supplements<sup>4</sup>. In addition, the co-occurrence of multiple mycotoxins such as aflatoxin B<sub>2</sub> (AFB<sub>2</sub>) and ochratoxin A (OTA) in the product can lead to additive or synergistic toxic effects complicating the assessment of health risks associated with these supplements<sup>5</sup>. These risks are intensified by inadequate storage practices and lacking regulatory oversight, which contribute to fungal growth and contamination<sup>2,6</sup>. Strengthening regulatory frameworks and improving public education are essential steps toward ensuring the safety of PBS<sup>7</sup>.

Upon ingestion, mycotoxins like AFB<sub>1</sub> are primarily metabolized in the liver, where they are converted into highly reactive intermediates. These intermediates form DNA adducts, such as aflatoxin-N<sup>7</sup>-guanine, which play a major role in promoting mutagenesis and carcinogenesis<sup>8</sup>. The genotoxicity of aflatoxins is widely documented, with studies showing that these toxins induce oxidative stress and DNA strand breakage, contributing to severe health outcomes, including liver cancer<sup>9</sup>. The interaction between aflatoxins and other environmental factors, such as hepatitis B virus infection, further elevates the risk of hepatocellular carcinoma (HCC). Understanding these interactions is essential to assessing the comprehensive risks associated with mycotoxin exposure<sup>10</sup>.

Aflatoxins and OTA are among the most significant mycotoxins due to their widespread occurrence and pronounced toxicological effects. Studies reveal that these mycotoxins frequently co-occur in various food commodities, posing health risks. For instance, a study in Côte d'Ivoire highlighted a high prevalence of co-contamination, with multiple mycotoxins detected in foodstuffs, including OTA and AFB<sub>1</sub><sup>11</sup>. Furthermore, the interaction between these two toxins has been shown to increase their toxic effects. Research indicates that co-exposure to OTA and AFB<sub>1</sub> results in synergistic toxicity, amplifying cytotoxic and genotoxic impacts compared to individual exposures<sup>12,13</sup>. These effects are particularly concerning in vulnerable populations, such as children, where dietary exposure can lead to significant health risks<sup>14,15</sup>.

In response to these public health concerns, regulatory agencies have set limits on mycotoxin levels in food products to minimize exposure. In Malaysia, the Ministry of Health regulates mycotoxins, with aflatoxin levels in certain food products set at 5 µg/kg<sup>16</sup>. Globally, organizations such as the Codex Alimentarius Commission and the European Commission have established stringent guidelines to control mycotoxin contamination, defining maximum residue limits for mycotoxins in various food items which are 5 µg/kg for AFB<sub>1</sub>, 10 µg/kg for total aflatoxins, and 3 µg/kg for OTA<sup>17,18</sup>. However, challenges remain, particularly due to Malaysia's tropical climate, which promotes fungal growth and subsequent mycotoxin production. Inadequate storage and transportation conditions worsen contamination risks, highlighting the necessity for more stringent regulations and enhanced food safety measures<sup>19</sup>.

Malaysia's tropical climate, marked by high humidity and temperatures, provides suitable conditions for the growth of mycotoxigenic fungi, such as *Aspergillus* and *Fusarium*<sup>17</sup>. This climatic condition along with inadequate post-harvest practices, raises the possibility of mycotoxin contamination in food products, including PBS. Research has shown that the occurrence of aflatoxins and other mycotoxins in agricultural products is significantly affected by these environmental factors<sup>17</sup>. The economic consequences of mycotoxin contamination in Malaysia are also considerable, leading to reduced agricultural productivity and increased healthcare costs from foodborne illnesses. With increasing temperatures due to climate change, the frequency and severity of mycotoxin contamination are forecasted to increase<sup>20</sup>.

The public health burden of mycotoxin exposure in Malaysia is demonstrated by the rising incidence of liver cancer, which has been linked to dietary aflatoxin exposure. Studies indicate that AFB<sub>1</sub> is a significant contributor to liver cancer, particularly in areas with increased incidence of hepatitis B virus infection<sup>21</sup>. Malaysia is among the countries with the highest liver cancer incidence, with dietary aflatoxin exposure recognized as a major risk factor<sup>22</sup>. Beyond cancer, chronic exposure to mycotoxins has been associated with other health concerns, such as stunting and immune dysfunction<sup>23</sup>. The combined effects of exposure to multiple mycotoxins further worsen these health risks, highlighting the necessity for thorough risk assessments and targeted public health interventions<sup>24</sup>.

The risk assessment of mycotoxins using Margin of Exposure (MOE) approach is essential for understanding their health impacts. Studies have highlighted alarming MOE values for aflatoxins; for example, in Indonesia, MOEs in maize and peanuts samples were generally below 10,000, signifying substantial health risks<sup>25</sup>. A systematic review further estimated that chronic aflatoxin exposure could contribute to 4.6% to 28.2% of global HCC cases, emphasizing the urgent need for effective risk management<sup>26</sup>. In Tanzania, recent studies revealed that aflatoxin-induced liver cancer poses a significant health burden, with MOE values pointing to serious concerns for those consuming contaminated food<sup>27</sup>. The MOE approach remains a critical tool for guiding regulatory actions and interventions to reduce mycotoxin-related risks<sup>28</sup>.

Given the serious health risks associated with mycotoxin contamination in PBS, it is important to mitigate these risks through enhanced regulation, testing, and public education. Malaysia's current regulatory frameworks remain insufficient with limited monitoring and enforcement enabling contaminated products to reach consumers<sup>29</sup>. As the demand for natural supplements increases, so does the urgency for stricter safety standards. In Southeast Asia, where environmental conditions and agricultural practices lead to the high prevalence of mycotoxins, efforts to reduce contamination must prioritize improving storage practices, strengthening regulatory oversight, and raising consumer awareness about the hazards of contaminated supplements<sup>17,30</sup>. Hence, this study aims to assess the health hazard posed by PBS containing mycotoxins using MOE and cancer risk approaches.

Methods

Sample collection

The samples were collected from March to December 2023, focusing on commercially available herbs in Malaysia. A total of 14 samples were obtained from local drugstores and online marketplaces to capture the influence of Malaysia’s varying climatic conditions on mycotoxin production. This approach provides a broader understanding of real-world contamination, and we accounted for variability during data analysis to ensure robust findings. In addition, these samples were chosen based on their inclusion in a prior cross-sectional survey that identified the most commonly used herbs in the region<sup>31</sup>. The selection criteria required the products to have been manufactured between 2022 and 2023 to reflect current market conditions. After collection, the samples were sealed in air-tight plastic bags, labelled, and stored at − 20 °C at the Institute of Bioscience, Universiti Putra Malaysia, until further analysis.

Chemicals and reagents

High-performance liquid chromatography (HPLC)-grade methanol and acetonitrile were obtained from R&M Chemicals (United Kingdom) for the extraction and testing of aflatoxins. Standards for AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA mycotoxins were sourced from Sigma-Aldrich (United States). Reagents for the QuEChERS extraction method, including Magnesium Sulfate (MgSO<sub>4</sub>) and acetonitrile, were purchased from R&M Chemicals (United Kingdom), while glacial acetic acid was acquired from Merck (Germany). These materials were essential for ensuring high purity and precision in the detection process.

Equipment and testing conditions

Chromatographic separation was performed using an Agilent G6125B LCMS system (Agilent, Santa Clara, USA) with a reversed-phase Supelco C18 (150 mm in length×4.6 mm in internal diameter, 5 μm particle size, Sigma Aldrich in Missouri, USA) with a quaternary pump, a vacuum degasser, an autosampler, and a thermostatic column oven kept at 35 °C. The extract was filtered through a 0.2 μm Nylon Syringe Filter (Corning, Massachusetts, USA) before analysis. The mobile phase consisted of nanopure water containing 0.1% formic acid (v/v)(solvent A) and acetonitrile containing 0.1% formic acid (v/v)(solvent B), applied with gradient elution. The elution starts at a concentration of 95% of solvent B and gradually reduces to 80% over a period of 1 min. Afterwards, it subsequently reduced to 75% during an interval of 1 min and remained at that level for an additional 2 min in isocratic mode. Then, solvent B was adjusted to 0% for a duration of 1 min and then restored at starting condition for an additional 1 min. The system operated at a flow rate of 0.3 mL/min, with an injection volume of 5 μL, and the column temperature was maintained at 40 °C.

Concentrations were determined using an Agilent tandem mass spectrometer, manufactured by Agilent in Santa Clara, USA, operating in electron spray ionization (ESI) positive ion mode. The quantification of the mass spectrometry (MS) system was operated in multiple reaction monitoring (MRM) mode. Details of MS parameters (declustering potential and collision energy), and retention time are described in Table 1.

QuEChERS extraction

The samples were homogenized and weighed to 2.5 g, then mixed with 7.5 mL of ultra-pure water. After homogenization with 10 mL of acetonitrile containing 1% acetic acid, the mixture was shaken for 30 minutes. The extraction process included purification with 4g anhydrous MgSO<sub>4</sub> and centrifugation at 1822 g for 10 min. The supernatant underwent solid-phase extraction using a dispersive solid-phase extraction (dSPE) tube, followed by shaking and centrifugation at 2200 g for 5 minutes. The extract was diluted, filtered, and stored in amber vials at − 20 °C until analysis by LC-MS.

Validation of the testing method

The method was validated by evaluating sensitivity through limits of detection (LOD) and quantification (LOQ), adhering to the criteria established by Afsah-Heji and co-workers<sup>22</sup>. Linearity was assessed by injecting a series of aflatoxin standards at varying concentrations into the LC–MS system and recording the corresponding responses. Recovery tests were performed by spiking samples with known concentrations of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA, followed by extraction and calculation of recovery rates. The method’s linearity and precision were confirmed, with coefficient of determination (R<sup>2</sup>) values exceeding 0.99<sup>32</sup>.

Exposure evaluation

The estimated daily intake (EDI) of aflatoxins was calculated based on the concentration of mycotoxins detected in the samples and the average daily consumption rates of the products, according to data from the Malaysian population. The formula used was EDI = (Average concentration of mycotoxins × Average daily consumption)/Average body weight, with a body weight of 60 kg for the Malaysian population<sup>33</sup>.

| Mycotoxins       | Ionization mode | Retention time (mins) | Parent ion (m/z) | Collision energy | Declustering potential |
|------------------|-----------------|-----------------------|------------------|------------------|------------------------|
| AFB <sub>1</sub> | ESI+            | 6.47                  | 313              | 55 V             | 30 V                   |
| AFB <sub>2</sub> | ESI+            | 5.13                  | 316              |                  |                        |
| OTA              | ESI+            | 6.67                  | 404              |                  |                        |

Table 1. LCMS condition for AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA.

## Risk characterization

To assess the public health risk, both the Margin of Exposure (MOE) and cancer risk approaches were employed. The MOE was calculated by dividing the benchmark dose lower confidence limit (BMDL<sub>10</sub>) by the EDI. For AFB<sub>1</sub> and AFB<sub>2</sub>, the BMDL<sub>10</sub> is set at 0.4 µg/kg bw/day based on liver tumor incidences in rats<sup>34</sup> while BMDL<sub>10</sub> is set at 14.5 µg/kg bw/day for OTA based on kidney tumor incidences in rats<sup>35</sup>. An MOE value below 10,000 suggests a potential health concern as defined by the Scientific Committee of the European Food Safety Authority (EFSA) which include the inter-species and intra-species differences, the nature of the carcinogenic process, and the reference point on the dose–response curve factors<sup>36</sup>.

Additionally, a quantitative risk assessment for liver cancer was conducted, incorporating the risk associated with HCC and kidney cancer attributable to the consumption of PBS was estimated based on the exposure, and the carcinogenic potency of AFB<sub>1</sub>. For AFB<sub>2</sub> and OTA, the in vivo data are not sufficient to derive potency factors. Considering that AFB<sub>1</sub> is the major contributor to the exposure, the same potency as for AFB<sub>1</sub> was assumed for AFs and OTA<sup>37</sup>. The potency values for AFs/OTA estimated by Joint FAO/WHO Expert Committee on Food Additives (JECFA), which corresponded to 0.3 cancers/year/100,000 population/ng/kg body weight/day in HBsAg-positive individuals, and 0.01 cancers/year/100,000 population/ng/kg body weight/day in HBsAg-negative individuals, were adopted for this calculation. A HBsAg positivity rate of 5.24% was determined for the Malaysian population<sup>38</sup>. Therefore, the carcinogenic potency ( $P_{\text{cancer}}$ ) was estimated  $P_{\text{cancer}} = (0.3 \times 0.054) + (0.01 \times 0.9476) = 0.025$  cancers/year/100,000 individuals/ng AFB<sub>1</sub>/kg bw/day.

The estimated risk of cancer in the adult population of Malaysia was calculated based on the total dietary exposure to AFs and OTA in PBS and the average potency of the population using the following equation: Cancer risk = Exposure × Average potency. The percentage of cancer attributable to dietary exposure to AFs and OTA in PBS was calculated as the ratio between the risk of the target population and the age-standardized incidence rate for HCC and kidney cancer per 100,000 population per year for both sexes<sup>39,40</sup>.

## Results

### Collection of plant-based supplements for analysis

Table 2 shows the product description of the PBS analyzed in the present study. All the PBS were bought from physical drug stores and online shopping platforms. All the samples were originated from China and Malaysia but marketed in Malaysia.

### Method validation

The LOD and LOQ for this investigation have been determined by evaluating the instrumental linearity. The calibration curves for each analyte may be seen in Supplementary Materials A. The correlation coefficients ( $R^2$ ) values are consistently over 0.980 in all cases, specifically 0.997 for AFB<sub>1</sub>, 0.999 for AFB<sub>2</sub>, and 0.997 for OTA. The level of all mycotoxins detected were adjusted from a previous study recommended by a study conducted by Mbisana and co-workers<sup>29</sup> that matches with our present study. The percentage of recovery used was 90.10% for AFB<sub>1</sub>, 92.07% for AFB<sub>2</sub>, and 99.16% for OTA.

### Liquid chromatography with mass spectrometry (LC–MS) analysis

The LC–MS analysis was performed to detect and quantify the presence of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA in the PBS. The quantification study revealed the presence of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA at 6.4, 5.1, and 6.6 min, respectively (Fig. 1).

Among the 14 samples tested using LC–MS, AFB<sub>1</sub> was detected in 4 samples (28.57%), AFB<sub>2</sub> was detected in all 14 samples (100%), and OTA was detected in 6 samples (42.86%) (Table 3). Both Sample B2 and Sample B10 from the PBS samples were found to have all three contaminants. Sample B2 contains 2.276 µg/kg of AFB<sub>1</sub>, 233.073 µg/kg of AFB<sub>2</sub>, and 30.565 µg/kg of OTA. The values for AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA in sample B10 are 9.470 µg/kg, 187.389 µg/kg, and 14.946 µg/kg, respectively. Figure 1 also showed the chromatogram illustrating the co-existence of all three mycotoxins identified in sample B10.

Based on the list of PBS in Table 3, a noteworthy revelation emerged concerning the B2 and B10 PBS samples. These samples exhibited positivity for all tested mycotoxins contaminants, namely AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA. The botanical ingredients identified in these positive samples encompass *Scutellaria Baicalensis Radix*, *Radix Angelicae*, *Fructus*, and *Semen Arecae*, unveiling a potential correlation between the presence of these botanical elements and the contamination profile. In addition, all samples that were detected positive with mycotoxins were exceeded the European regulatory limit of 10 µg/kg for total aflatoxins and 3 µg/kg for OTA except sample B4 for OTA exposure raises intriguing questions about potential sources and routes of contamination.

### Estimated daily intake (EDI)

The average duplicate analysis was utilized to compute the EDI of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA. The EDIs were computed based on the quantities of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA detected in the PBS (Table 4), following the recommended daily intake by the supplier. The EDI of PBS varied from sample B11 contaminated with AFB<sub>1</sub> at a concentration of 0.000001 µg/kg bw/day, to sample B3 contaminated with AFB<sub>2</sub> at a concentration of 0.064 µg/kg bw/day.


### Risk assessment of PBS containing mycotoxins

The risk assessment of PBS was calculated using MOE approach to determine whether the consumption of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA through PBS should be considered a high or low priority for risk management (Table 4). MOEs with values below 10,000 are considered a high priority for risk management. It was observed that samples B2, B9, and B10 included AFB<sub>1</sub>, all PBS samples contained AFB<sub>2</sub>, and samples B2, B3, B6, and B10 contained OTA. These positive PBS samples exhibited MOE values below 10,000, except for sample B11 (AFB<sub>1</sub>), B1 (OTA), and B4 (OTA). Regarding AFB<sub>2</sub>, it was observed that all PBS samples have values below 10,000 and are therefore prioritized for risk management.

| Sample no | Product name                                 | Product presentation | Dosage                  | Botanical ingredients   | Country of origin | Function   |
|-----------|--|----------------------|-------------------------|---|-------------------|--|
| B1        | Teck Aun Chi-Kit Pills                       | Tablet               | 1 sachet, 4 times/day   | <i>Rhizoma Atractylodis M</i> , <i>Oleum Menthae</i> , <i>Herba Menthae</i> , <i>Pericarpium Citi R</i> , <i>Fructus Citri</i> , <i>Radix Glycyrrizae</i> , <i>Radix Aucklandiae</i> , <i>Radix Angelicae</i> , <i>Herba Asari</i> , <i>Fructus Chaenomelis</i> , <i>Poria</i> , <i>Semen Arecae</i> , <i>Herba Pogostemonis</i> , <i>Fructus Amomi</i>   | Malaysia          | Traditionally used for stomachache, minor diarrhoea, minor vomiting, indigestion, and motion sickness  |
| B2        | Fa Zhi Tan                                   | Tablet               | 2 tablets, 4 times/day  | <i>Olibanum</i> , <i>Scutellaria Baicalensis Radix</i> , <i>Sanguisorba Officinalis L Radix</i> , <i>Radix Et Rhizoma Rhei</i> , <i>Radix Angelicae Sinensis Extract</i> , <i>Ledebouriella Divaricata Radix</i> , <i>Fructus Aurantii Immaturus</i> , <i>Flos Sophorae</i> , <i>Arecae Semen</i> , <i>Angelicae Dahuricae Radix</i> , <i>Rhizoma Imperatae</i>   | Malaysia          | Traditionally used to relieve pain and itchiness to piles and for relief of mild constipation  |
| B3        | Chui Feng So Ho Wan                          | Tablet               | 2 tablets, 2 times/day  | <i>Radix Glycyrrhiza uralensis</i> , <i>Fructus Amomum Villosum Lour</i> , <i>Rhizoma Ligusticum Chuanxiong</i> , <i>Radix Angelica Dahurica</i> , <i>Radix Ledebouriella Divaricata</i> , <i>Fructus Amomum Kravanh</i> , <i>Rhizoma Notopterygium Incisum</i> , <i>Honey</i> , <i>Lignum Santalum Album</i> , <i>Semen Areca Catechu</i> , <i>Herba Mentha Haplocalyx</i> , Excipient: <i>Menthol</i>   | Malaysia          | Traditionally used for symptomatic relief of stomach discomfort, flatulence, headache, mild vomiting, cough, and flu, dispels wind for women after childbirth  |
| B4        | Chuan Ann Tong Sian Ke Sen                   | Tablet               | 10 tablets, 2 times/day | NA  | Malaysia          | This medicine is traditionally used to relieve joint pain, smooth the menstrual cycle, for women after childbirth, for health, and energy  |
| B5        | Bao Ying Dan                                 | Powder               | 2 bottles/day           | <i>Calculus Bovis</i> , <i>Margarita Pteria Martensii</i> , <i>Rhizoma Acorus Tatarinowii</i> , <i>Succinum</i> , <i>Aisaema Cum Bile</i> , <i>Concretion Silicea Bambusa Textilis</i> , <i>Rhizoma Paris Polyphylla</i> , <i>Radix Saposhnikovia Divaricata</i> , <i>Rhizoma Pinellia Ternata</i> , <i>Bulbus Fritillaria Cirrhosa</i> , <i>Radix Scutellaria Baicalensis</i> , <i>Ramulus Uncaria Rhynchophylla</i> , <i>Radix Curcuma Wenyulin</i> , <i>Herba Mentha Haplocalyx</i> , <i>Rhizoma Gastrodia Elata</i> , <i>Periostracum Cicadae Cryptotympana Pustulata</i> | China             | Traditionally used for phlegm, vomiting, crying at night, fever, cold, and cough   |
| B6        | Lotus Brand Ba Bao Zhu Po Plus Jing Feng San | Powder               | 1 spoon, 3 times/day    | <i>Resina Succinum</i> , <i>Concha Cryptotympana Pustulata</i> , <i>Radix Glycyrrhiza Uralensis</i> , <i>Radix Trichosanthes Kirilowii</i> , <i>Caulis Polygoni Multiflori Preparata</i>  | Malaysia          | Traditionally used for sleep difficulty  |
| B7        | Kwei Be Wan                                  | Tablet               | 8 tablets, 3 times/day  | <i>Radix Codonopsis</i> , <i>Poria</i> , <i>Semen Ziziphi Spinosa</i> , <i>Radix Angelicae Sinensis</i> , <i>Radix Aucklandiae</i> , <i>Rhizoma Atractylodis Macrocephalae</i> , <i>Arillus Longan</i> , <i>Radix Astragali</i> , <i>Fructus Jujubae</i>  | China             | Traditionally used for general health, improving appetite, and relief of fever   |
| B8        | Kapsul Herba Kempisa                         | Capsule              | 6 capsules/day          | <i>Folium Cassia Alata</i> , <i>Folium Cassia Obtusifolia</i> , <i>Semen Nigella Sativa</i> , <i>Folium Cinnamomum Iners</i> , <i>Fructose</i>  | Malaysia          | Remedy for flatulence and blood wind. Treat constipation, deflate the stomach, and relieve urination. Suitable for those trying to get pregnant  |
| B9        | D' Senna Plus Capsule                        | Capsule              | 3 capsules/day          | <i>Senna</i>  | Malaysia          | Helps treat constipation, relieve bowel movements, detox the body, get rid of dirt in the intestines, slim weight loss program, treat worm problems, treat high blood pressure, treat diabetes and high sugar                  |
| B10       | Ubat Akar Teh Sejuk Cap Tan Ngan Lo          | Leaves               | 1 sachet, 4 times/day   | <i>Folium Camellia Sinensis</i> , <i>Cortex Schefflera Octophylla</i> , <i>Radix Bupleurum chinense</i> , <i>Radix Glycyrrhizae Uralensis</i> , <i>Cortex Ilex Rotunda</i> , <i>Radix Scutellariae Baicalensis</i> , <i>Semen Cleistocalyx Operculatus</i> , <i>Herba Progesterone Cablin</i> , <i>Herba Schizonepetae Tenuifolia</i> , <i>Radix Angelica Pubescens</i> , <i>Pericarpium Citri Reticulatae</i> , <i>Fructus Crataegi Pinnatifida</i> , <i>Radix Scrophularia Ningpoensis</i> , <i>Semen Arecae Catechu</i> , <i>Herba Menthae Haplocalyx</i>                  | Malaysia          | Help in moderating health problems such as sore throats, flu, and lethargy   |
| B11       | Capsule Pegaga Bidan Liza                    | Capsule              | 2 capsules, 2 times/day | <i>Centella Asiatica</i>  | Malaysia          | Enhancing facial radiance removes dark spots on the face, shrinks the uterus, relieves body aches, and relieves headaches  |
| B12       | Jamu Nenek Kapsul Rapat Plus                 | Capsule              | 2 capsules, 2 times/day | <i>Hippocratea indica</i> , <i>Piper nigrum</i> , <i>Trachyspermum ammi</i> , <i>Quercus infectoria</i> , <i>Labisia pumilia lin</i>  | Malaysia          | Treats menstruation and stabilises the menstrual cycle. Treating whiteness, bad smell, and itching in the intimate parts of women. Raises the complexion and stays young   |
| B13       | Jus Mengkudu Bermadu                         | Liquid               | 3 spoons, 1 time/day    | <i>Phoenix dactylifera</i> , <i>Nigella sativa</i> , <i>Piper betle</i> , <i>Crocus sativus</i>   | Malaysia          | Helps to regulate the immune system, diabetes, cholesterol, and blood pressure   |
| B14       | Serai Mas Kurma Hidayah Plus Liquid          | Liquid               | 2 spoons, 1 time/day    | <i>Punica granatum</i> , <i>Zingiber officinale</i> , <i>Quercus infectoria</i> , <i>Elephantopus scaber</i> , <i>Plectranthus</i> , <i>Labisia pumila</i>  | Malaysia          | Helps to improve physical fitness and mental intelligence in addition to helping to recover various types of diseases that affect health. It is suitable for the whole family to practice obtaining an optimal level of health |

**Table 2.** Product description of the PBS analyzed in the present study. NA Data not available/not provided by the supplier.





**Fig. 1.** Example of chromatogram of the co-existence of all contaminants studies which are AFB<sub>1</sub> (at 6.47 min), AFB<sub>2</sub> (at 5.13 min), and OTA (at 6.67 min) in sample B10.

| Sample no | AFB <sub>1</sub> (µg/kg) | AFB <sub>2</sub> (µg/kg) | OTA (µg/kg)         |
|-----------|--------------------------|--------------------------|---------------------|
| B1        | ND                       | 277.611 <sup>b</sup>     | 6.353 <sup>c</sup>  |
| B2        | 2.276 <sup>b</sup>       | 233.073 <sup>b</sup>     | 30.565 <sup>c</sup> |
| B3        | ND                       | 238.381 <sup>b</sup>     | 31.131 <sup>c</sup> |
| B4        | ND                       | 26.373 <sup>b</sup>      | 0.455               |
| B5        | ND                       | 159.544 <sup>b</sup>     | ND                  |
| B6        | ND                       | 239.685 <sup>b</sup>     | 61.898 <sup>c</sup> |
| B7        | ND                       | 215.854 <sup>b</sup>     | ND                  |
| B8        | ND                       | 262.796 <sup>b</sup>     | ND                  |
| B9        | 66.377 <sup>a,b</sup>    | 295.044 <sup>b</sup>     | ND                  |
| B10       | 9.470 <sup>a,b</sup>     | 187.389 <sup>b</sup>     | 14.946 <sup>c</sup> |
| B11       | 0.087 <sup>b</sup>       | 167.025 <sup>b</sup>     | ND                  |
| B12       | ND                       | 157.969 <sup>b</sup>     | ND                  |
| B13       | ND                       | 155.400 <sup>b</sup>     | ND                  |
| B14       | ND                       | 117.305 <sup>b</sup>     | ND                  |

**Table 3.** Levels of mycotoxins detected in PBS samples. ND Not detected. <sup>a</sup>Exceeded the European regulatory limit of 5 µg/kg for AFB<sub>1</sub>. <sup>b</sup>Exceeded the European regulatory limit of 10 µg/kg for total aflatoxins. <sup>c</sup>Exceeded the European regulatory limit of 3 µg/kg for OTA.

Apart from the qualitative MOE ratio, which was established by EFSA for carcinogenic and genotoxic substances, the characterization of risk results from oral exposure to AFs and OTA was evaluated using the quantitative cancer risk estimation proposed by the JECFA<sup>42</sup>. Table 5 shows the lowest (lower bound; LB) and highest (upper bound; UB) estimates of cancer risk and the percentage of HCC and kidney cancer caused by exposure to AFs and OTA in our PBS samples. The exposure of AFB<sub>1</sub> from the consumption of the PBS samples ranged from 0 to 1.11 ng/kg bw/day, while the exposure of AFB<sub>2</sub> ranged from 1.32 to 116.55 ng/kg bw/day. The exposure of OTA, which was detected in 6 samples (42.86%), ranged from 0 to 8.30 ng/kg body weight/day. The estimated cancer risk based on the potency estimate of 0.025 cancers/100,000 population/year per ng/kg bw/day for all mycotoxins tested ranged from 0 to 0.03 for AFB<sub>1</sub>, 0.03 to 2.91 for AFB<sub>2</sub> and 0 to 0.21 cancers/100,000 population/year per ng/kg body weight/day for OTA. For all samples, the estimated percentage of HCC was between 0 and 0.44% due to AFB<sub>1</sub> exposure and between 0.52% and 46.25% due to AFB<sub>2</sub> exposure. According to estimates, up to 8.65% of kidney cancer cases could be attributed to OTA exposure.

## Discussion

This study offers relevant insights into the occurrence of aflatoxins (AFB<sub>1</sub>, AFB<sub>2</sub>) and ochratoxin A (OTA) in PBS sold in Malaysia. Among the 14 PBS samples analyzed, all were contaminated with AFB<sub>2</sub>, while over 28% and 42% were contaminated with AFB<sub>1</sub> and OTA, respectively. Samples B2 and B10 exhibited particularly had higher contamination, with AFB<sub>1</sub> concentrations of 2.276 µg/kg and 9.470 µg/kg. AFB<sub>2</sub> and OTA levels in these samples were also notably high. These results are consistent with previous studies documenting mycotoxin contamination in herbal supplements across Southeast Asia<sup>3,43</sup>. The presence of botanical ingredients like

| Sample no | Estimated daily intake (µg/kg bw/day) |                  |          | Margin of exposure |                  |         |
|-----------|---------------------------------------|------------------|----------|--------------------|------------------|---------|
|           | AFB <sub>1</sub>                      | AFB <sub>2</sub> | OTA      | AFB <sub>1</sub>   | AFB <sub>2</sub> | OTA     |
| B1        | ND                                    | 0.042            | 0.001    | ND                 | 9*               | 15 215  |
| B2        | 0.001                                 | 0.062            | 0.008    | 659*               | 6*               | 1 779*  |
| B3        | ND                                    | 0.064            | 0.008    | ND                 | 6*               | 1 746*  |
| B4        | ND                                    | 0.001            | 0.000023 | ND                 | 303*             | 637,281 |
| B5        | ND                                    | 0.003            | ND       | ND                 | 150*             | ND      |
| B6        | ND                                    | 0.012            | 0.003    | ND                 | 33*              | 4685*   |
| B7        | ND                                    | 0.018            | ND       | ND                 | 22*              | ND      |
| B8        | ND                                    | 0.013            | ND       | ND                 | 30*              | ND      |
| B9        | 0.001                                 | 0.005            | ND       | 361*               | 81*              | ND      |
| B10       | 0.001                                 | 0.019            | 0.001    | 422*               | 21*              | 9 701*  |
| B11       | 0.000001                              | 0.003            | ND       | 276,846            | 143*             | ND      |
| B12       | ND                                    | 0.003            | ND       | ND                 | 151*             | ND      |
| B13       | ND                                    | 0.117            | ND       | ND                 | 3*               | ND      |
| B14       | ND                                    | 0.059            | ND       | ND                 | 6*               | ND      |

**Table 4.** Estimated Daily Intakes (EDI) and Margin of Exposure (MOE) of mycotoxins detected in PBS samples. ND Not detected. \*MOE < 10,000.

| Mycotoxins       | Exposure (ng/kg bw/day) <sup>a</sup> |        | Estimated cancer risk (no. of cancers/100,000 population/year) <sup>b</sup> |      | % Cancer incidence |        |
|------------------|--------------------------------------|--------|---|------|--------------------|--------|
|                  | LB                                   | UB     | LB  | UB   | LB                 | UB     |
| AFB <sub>1</sub> | 0                                    | 1.11   | 0   | 0.03 | 0*                 | 0.44*  |
| AFB <sub>2</sub> | 1.32                                 | 116.55 | 0.03  | 2.91 | 0.52*              | 46.25* |
| OTA              | 0                                    | 8.30   | 0   | 0.21 | 0**                | 8.65** |

**Table 5.** The lowest and highest estimation of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA exposure, cancer risk, and percentage of cancer incidence in Malaysia. <sup>a</sup>Based on the mean bodyweight of the general adult population of 60 kg. <sup>b</sup>Calculated based on general adult population potency estimate of 0.025 cancers/100,000 population/year per ng/kg bw/day for AFs and OTA. \*Based on the age-standardized incidence rate for liver cancer of 6.3/100,000 individuals/year<sup>40</sup>. \*\*Based on the age-standardized incidence rate for kidney cancer of 2.4/100,000 individuals/year<sup>39</sup>.

*Scutellaria baicalensis* and *Semen arecae* in the most contaminated samples suggests a possible link between specific plant species and increased mycotoxin contamination, emphasizing the need for further investigation into contamination mechanisms<sup>44</sup>.

The EDI of mycotoxins from these PBS products indicates significant health risks, particularly for AFB<sub>2</sub>, as all samples went beyond the MOE safety threshold of 10,000. Samples B2 and B10 posed the highest risk, with MOE values for AFB<sub>2</sub> as low as 6 and 21, respectively, highlighting the urgent need for risk management measures. These findings are consistent with studies that have reported elevated EDI levels of aflatoxins in dietary supplements, often exceeding the safety limits set by the EFSA<sup>34,45</sup>. Additionally, the co-occurrence of AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA in these supplements raises about possible synergistic toxic effects, as indicated by prior research on mycotoxin mixtures<sup>23</sup>.

The quantitative cancer risk assessment in this study revealed a significant risk of liver cancer linked to the consumption of contaminated PBS, especially those containing AFB<sub>1</sub> and AFB<sub>2</sub>. The estimated dietary exposure to AFB<sub>2</sub> ranged from 1.32 to 116.55 ng/kg bw/day, contributing to an elevated risk of HCC, particularly in populations with frequent consumption of PBS<sup>46</sup>. These results are aligned with other studies that have identified increased cancer risks associated with aflatoxin exposure in vulnerable populations<sup>47</sup>.

The findings of this study raise significant concerns regarding the health risks associated with consuming contaminated PBS, particularly for vulnerable groups such as children and immunocompromised individuals. Certain samples, such as B9, contained significant levels of mycotoxins, with AFB<sub>1</sub> reaching 66.377 µg/kg—far exceeding the regulatory limit of 5 µg/kg for total aflatoxins set by the Malaysian Food Act 1983<sup>3</sup>. Similar issues have been reported in other studies, which have documented elevated levels of mycotoxins in herbal supplements, pointing to a global concern that requires regulatory intervention<sup>4,31</sup>.

The widespread AFB<sub>2</sub> contamination in Malaysian PBS, coupled with low MOE values and increased cancer risks, necessitates immediate regulatory intervention. The co-occurrence of multiple mycotoxins in some samples indicates that consumers may face greater health risks beyond those associated with individual toxins. Continued investigation is warranted to investigate the specific botanical and environmental factors leading to

contamination in these products, as well as the long-term health impacts of chronic mycotoxin exposure through dietary supplements<sup>34,45</sup>. Implementing robust regulatory measures and comprehensive product monitoring will be vital in mitigating the public health risks posed by mycotoxin contamination in plant-based supplements.

Ensuring the safety of PBS necessitates strict quality control measures across the entire supply chain, from cultivation to packaging. This study emphasizes the necessity of following good agricultural practices, maintaining proper storage conditions, and conducting regular mycotoxin testing. The findings are consistent with other research that points to the importance of robust regulatory frameworks to ensure the safety of dietary supplements<sup>29</sup>. Although regulatory frameworks exist in Malaysia, stronger enforcement is required to prevent contaminated products from reaching consumers.

This study has several limitations. First, the sample size of 14 PBS, while sufficient for preliminary evaluation, may not fully represent the diversity of products available in Malaysia, as it primarily focuses on more accessible, popular items. Expanding the sample to include a broader range of products and manufacturers would provide a more comprehensive assessment. Despite the limited sample size, the findings offer valuable preliminary data on mycotoxin contamination in PBS available in the Malaysian market. Second, the study only examined AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA, excluding other mycotoxins such as fumonisins and zearalenone, which may have led to an underestimation of the total mycotoxin burden. Future research should include a wider range of mycotoxins to more comprehensive risk assessment. Additionally, the MOE and cancer risk approaches used for risk assessment do not account for cumulative exposure or interactions between mycotoxins, which may result in additive or synergistic effects. Future research should aim to address these complexities to provide a more comprehensive evaluation of combined mycotoxin health risks. Finally, the study assumed adherence to recommended dosages, though actual consumption patterns may vary, impacting the EDI and overall risk assessment. Future studies should incorporate consumer behaviors data to better represent potential exposures.

## Conclusion

In conclusion, this study highlights the significant health risks associated with the presence of mycotoxins, specifically AFB<sub>1</sub>, AFB<sub>2</sub>, and OTA, in plant-based supplements sold in Malaysia. The detection of these toxic substances at levels exceeding regulatory limits points to the necessity of stricter quality control measures and stronger regulatory enforcement. The use of the EDI, MOE, and cancer risk approaches has provided important insights into the potential long-term health risks, particularly for vulnerable populations who regularly consume these supplements. Furthermore, the co-occurrence of multiple mycotoxins raises the cumulative risk, emphasizing the need for comprehensive testing for a wider range of contaminants in these products. Moving forward, it is essential that public health authorities and industry stakeholders collaborate to enhance the safety of plant-based supplements, ensuring compliance with safety standards and reducing consumer exposure to harmful mycotoxins.

## Data availability

Raw data within the manuscript is provided in Supplementary Materials B.

Received: 25 October 2024; Accepted: 1 January 2025

Published online: 07 January 2025

## References

- Ezekwesili-Ofili, J. O., Onyemelukwe, N. F., Agwaga, P. & Orji, I. The biolad and aflatoxin content of herbal medicines from selected states in Nigeria. *Afr. J. Tradit. Complement. Altern. Med.* **11**(3), 143 (2014).
- Altyn, I. & Twarużek, M. Mycotoxin contamination concerns of herbs and medicinal plants. *Toxins* **12**, 182 (2020).
- Victor Jeyaraj, S. V. et al. Aflatoxin tests in herbal products and its quantification: Latest updates. *Front. Nutr.* **9**, 956077 (2022).
- Vepríkova, Z. et al. Mycotoxins in plant-based dietary supplements: Hidden health risk for consumers. *J. Agric. Food Chem.* **63**(29), 6633–6643 (2015).
- Rocha-Miranda, F. & Venâncio, A. Mycotoxigenic fungi in plant-based supplements and medicines. *Curr. Opin. Food Sci.* **30**, 27–31 (2019).
- Zhang, L., Dou, X. W., Zhang, C., Logrieco, A. F. & Yang, M. H. A review of current methods for analysis of mycotoxins in herbal medicines. *Toxins* **10**, 65 (2018).
- Qin, L. et al. Occurrence and analysis of mycotoxins in domestic Chinese herbal medicines. *Mycology* **11**, 126–146 (2020).
- Johnson, N. M. et al. Complete protection against aflatoxin B<sub>1</sub>-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold. *Cancer Prev. Res.* **7**(7), 658–665 (2014).
- Agar, G., Alpsoy, L., Bozari, S., Ertürk, F. A. & Yildirim, N. Determination of protective role of selenium against aflatoxin B<sub>1</sub>-induced DNA damage. *Toxicol. Ind. Health* **29**(5), 396–403 (2013).
- Liu, Y. & Wu, F. Global burden of Aflatoxin-induced hepatocellular carcinoma: A risk assessment. *Environ. Health Perspect.* **118**(6), 818–824 (2010).
- Manizan, A. L. et al. Multi-mycotoxin determination in rice, maize and peanut products most consumed in Côte d'Ivoire by UHPLC-MS/MS. *Food Control* **1**(87), 22–30 (2018).
- El, G.-B. et al. Cytotoxicity and genotoxicity induced by aflatoxin B<sub>1</sub>, ochratoxin A, and their combination in cultured Vero cells. *J. Biochem. Mol. Toxicol.* **24**(1), 42–50 (2010).
- Klarić, M., Rašić, D. & Peraica, M. Deleterious effects of mycotoxin combinations involving ochratoxin A. *Toxins (Basel)*. **5**(11), 1965–1987 (2013).
- Braun, D. et al. Monitoring early life mycotoxin exposures via LC-MS/MS breast milk analysis. *Anal. Chem.* **90**(24), 14569–14577 (2018).
- Huong, B. T. M. et al. Total dietary intake and health risks associated with exposure to aflatoxin B<sub>1</sub>, ochratoxin A and Fumonisins of children in Lao Cai Province Vietnam. *Toxins (Basel)* **11**(11), 638 (2019).
- Afsah-Hejri, L., Jinap, S. & Mirhosseini, H. Ochratoxin A quantification: Newly developed HPLC conditions. *Food Control*. **23**(1), 113–119 (2012).
- Afsah-Hejri, L., Jinap, S., Hajeb, P., Radu, S. & Shakibazadeh, S. A review on mycotoxins in food and feed: Malaysia case study. *Compr. Rev. Food Sci. Food Saf.* **12**(6), 629–651 (2013).



18. European Commission. Commission regulation (EC) no. 1881/2006 setting maximum levels for certain contaminants in foodstuffs. *Off. J. Eur. Union* **364**, 5–24 (2006).
19. Khalid, K., Napiyah, N., Ishak, R., Siva, R. & Abdullah, S. Occurrences of aflatoxins in selected rice production areas in Malaysia. *J. Trop. Plant Physiol.* **14**(1), 8 (2022).
20. Alshannaq, A. & Yu, J. H. Occurrence, toxicity, and analysis of major mycotoxins in food. *Int. J. Environ. Res. Public Health* **14**, 632 (2017).
21. Mohamed, R., Raihan, R., Azzeri, A. & Shabaruddin, F. H. Hepatocellular carcinoma in Malaysia and its changing trend. *Euroasian J. Hepatogastroenterol.* **8**(1), 54–56 (2018).
22. Mohd-Redzwan, S., Jamaluddin, R., Abd-Mutalib, M. S. & Ahmad, Z. A mini review on aflatoxin exposure in Malaysia: Past, present, and future. *Front. Microbiol.* **4**, 334 (2013).
23. Ezekiel, C. N. et al. Dietary risk assessment and consumer awareness of mycotoxins among household consumers of cereals, nuts and legumes in north-central Nigeria. *Toxins (Basel)*. **13**(9), 635 (2021).
24. Ekwomadu, T., Mwanza, M. & Musekiwa, A. Mycotoxin-linked mutations and cancer risk: A global health issue. *Int. J. Environ. Res. Public Health*. **19**, 7754 (2022).
25. Nugraha, A., Khotimah, K. & Rietjens, I. M. C. M. Risk assessment of aflatoxin B1 exposure from maize and peanut consumption in Indonesia using the margin of exposure and liver cancer risk estimation approaches. *Food Chem. Toxicol.* **113**, 134–144 (2018).
26. Adetunji, M. C., Aliko, O. P., Awa, N. P., Atanda, O. O. & Mwanza, M. Microbiological quality and risk assessment for aflatoxins in groundnuts and roasted cashew nuts meant for human consumption. *J. Toxicol.* **3**(2018), 1–11 (2018).
27. Kimanya, M. E. et al. Estimating the risk of aflatoxin-induced liver cancer in Tanzania based on biomarker data. *PLoS One* **16**(3), e0247281 (2021).
28. Monger, A., Mongar, P., Dorji, T. & Chhetri, V. The occurrence and human health risk assessment of total and aflatoxin B1 in selected food commodities in Bhutan. *Sci. Rep.* **14**(1), 16258 (2024).
29. Ong, J. Y., Tan, L. L. & Goh, C. T. Mycotoxin mitigation approaches in selected developed and developing countries. *Int. Food Res. J.* **30**(6), 1370–1391 (2023).
30. Reddy, K. R., Farhana, N. I. & Salleh, B. Occurrence of *Aspergillus* spp. and aflatoxin B1 in Malaysian foods used for human consumption. *J. Food Sci.* **76**(4), 99–104 (2011).
31. Ab Dullah, S. S., Sabran, M. R., Hasiah, A. H. & Abdullah, R. Risk assessment of aflatoxin B1 in herbal medicines and plant food supplements marketed in Malaysia using margin of exposure and RISK21 approaches. *Genes Environ.* **45**(1), 31 (2023).
32. Ouakhsase, A., Chahid, A., Choubbane, H., Aitmazirt, A. & Addi, E. A. Optimization and validation of a liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the determination of aflatoxins in maize. *Heliyon* **5**(5), e01565 (2019).
33. Leong, Y. H., Rosma, A., Latiff, A. A. & Ahmad, N. I. Exposure assessment and risk characterization of aflatoxin B1 in Malaysia. *Mycotoxin Res.* **27**(3), 207–214 (2011).
34. Schrenk, D. et al. Risk assessment of aflatoxins in food. *EFSA J.* <https://doi.org/10.2903/j.efsa.2020.6040> (2020).
35. Schrenk, D. et al. Risk assessment of ochratoxin A in food. *EFSA J.* **18**(5), e06113 (2020).
36. European Food Safety Authority (EFSA). Opinion of the scientific committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. *EFSA J.* **3**(10), 282 (2005).
37. Kortei, N. K. et al. Exposure and risk characterizations of ochratoxins A and aflatoxins through maize (*Zea mays*) consumed in different agro-ecological zones of Ghana. *Sci. Rep.* **11**(1), 23339 (2021).
38. Merican, I. et al. Chronic hepatitis B virus infection in Asian countries. *J. Gastroenterol. Hepatol. (Australia)* **15**, 1356–1361 (2000).
39. Arabsalmani, M. et al. Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern. *J. Nephropathol.* **6**(1), 30–42 (2016).
40. Goodarzi, E. et al. Global incidence and mortality of liver cancers and its relationship with the human development index (HDI): An ecology study in 2018. *World Cancer Res. J.* **6**, 12 (2019).
41. Mbisana, M., Rebagamang, T., Mogopodi, D. & Chibua, I. Development and validation of a QuEChERS-LC-MS/MS method for determination of multiple mycotoxins in maize and sorghum from Botswana. *Front. Fungal Biol.* <https://doi.org/10.3389/ffunb.2023.1141427> (2023).
42. JECFA. Safety evaluation of certain food additives and contaminants. World Health Organization (2002).
43. El Jai, A. et al. Occurrence of free and conjugated mycotoxins in aromatic and medicinal plants and dietary exposure assessment in the Moroccan population. *Toxins (Basel)* **13**(2), 125 (2021).
44. Ikeagwulonu, R. C. et al. Mycotoxin contamination of herbal medications on sale in Ebonyi State, Nigeria. *Int. J. Biol. Chem. Sci.* **14**(2), 613–625 (2020).
45. Kyei, N. N. A. et al. Assessment of multiple mycotoxin exposure and its association with food consumption: A human biomonitoring study in a pregnant cohort in rural Bangladesh. *Arch. Toxicol.* **96**(7), 2123–2138 (2022).
46. Kortei, N. K. et al. Exposure assessment and cancer risk characterization of aflatoxin M1 (AFM1) through ingestion of raw cow milk in southern Ghana. *Toxicol. Rep.* **9**, 1189–1197 (2022).
47. Zhang, W. et al. Probabilistic risk assessment of dietary exposure to aflatoxin B1 in Guangzhou, China. *Sci. Rep.* **10**(1), 7973 (2020).

## Acknowledgements

This research was supported by Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme (FRGS/1/2018/SKK06/UPM/02/10) and Universiti Putra Malaysia Grant (GP-IPM/2021/9705700).

## Author contributions

The authors' contributions were as follows—RA, NSK, and AHBA: designed the research; RA and NSK: performed the data analysis and interpretation, and wrote the initial draft of the manuscript; RA, MYA, AHBA: critically revised the manuscript; RA, NSK, SSA: conducted the research; RA and MYA: performed the LCMS analysis; RA: has primary responsibility for final content; and all authors: contributed to critically reviewing the manuscript, and read and approved the final manuscript.

## Funding

This research was supported by Ministry of Higher Education Malaysia under the Fundamental Research Grant Scheme (FRGS/1/2018/SKK06/UPM/02/10) and Universiti Putra Malaysia Grant (GP-IPM/2021/9705700).

## Declarations

## Competing interests

The authors declare no competing interests.

### Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-025-85280-z>.

**Correspondence** and requests for materials should be addressed to R.A.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025